Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28966482 | 0.92 | TSHR (0.47) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL5012163 | 0.92 | TSHR (0.47) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL11467631 | 0.91 | TSHR (0.36) | TSHRTHRB | |
| SCHEMBL18600561 | 0.90 | TSHR (0.44) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL2143395 | 0.89 | TSHR (0.41) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL9463372 | 0.89 | TSHR (0.35) | TSHRTHRB | |
| SCHEMBL6545836 | 0.81 | TSHR (0.47) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL9840435 | 0.81 | TSHR (0.38) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL7546695 | 0.80 | TSHR (0.40) | TSHRTHRBSLC22A1ALDH1A1HSD17B10 | |
| SCHEMBL1000117 | 0.75 | TSHR (0.35) | TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5521351-A | Method and apparatus for plasma surface treatment of the interior of hollow forms | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-05-28 | — | — | US | claimed |
| US-20090053155-A1 | Cosmetic Compositions Containing Silicone/Organic Copolymer | REVLON CONSUMER PRODUCTS CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1031344-A2 | Method of preparing silicone oil-in-water microemulsions | DOW CORNING CORPORATION (US) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053155-A1 | Cosmetic Compositions Containing Silicone/Organic Copolymer | LAGE3, CUTA, SMURF1 | TSHR 3542/4885THRB 3883/4885SLC22A1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.